News | April 24, 2014

Global Biopsy Devices Market Value to Grow Moderately by 2019

April 24, 2014 — The global biopsy devices market value will increase at a modest rate over the coming years, climbing from $506.4 million in 2013 to $602.4 million by 2019, at a compound annual growth rate (CAGR) of 2.93%, forecasts research and consulting firm GlobalData.

According to the company’s latest report, MediPoint: Biopsy Devices - Global Analysis and Market Forecasts, the biopsy devices market in emerging economies, such as China, India and Brazil, will increase at much higher CAGRS than the global rate, reaching shares of 24%, 10% and 6% by 2019, respectively.

Despite the modest global growth, several barriers are dampening the potential adoption of biopsy devices within a number of markets. Notably in the United States, reimbursement for image-guided breast biopsies has undergone drastic cuts, which GlobalData expects will have a significant effect on the adoption of more expensive vacuum-assisted biopsy (VAB) devices.

Joseph Gregory, GlobalData’s analyst covering surgical devices, said: “Additionally, routine screening for prostate cancer and breast cancer has come under scrutiny, as sophisticated clinical trials reveal that these interventions have a minimal impact on the cancer related mortality. This is a long-term setback for the adoption of biopsy devices in diagnosing these cancers, given that these criticisms could curb adoption of routine screening.”

While these challenges are likely to affect the biopsy devices market, GlobalData believes that current and future players can still position themselves to obtain a competitive advantage.

“The major European countries have general mass-screening programs for breast cancer detection and will be increasing their adoption of VAB devices over the forecast period. Additionally, the emerging economies are increasing their access to healthcare resources and showing a preference for more expensive core needle biopsy devices over fine needle aspiration devices,” Gregory concluded.

For more information: www.globaldata.com/QuotingGlobalData.aspx

Related Content

Cianna Medical featured its wire-free marker system on the exhibit floor of the breast imaging symposium in Hollywood, Fla.

Cianna Medical featured its wire-free marker system on the exhibit floor of the breast imaging symposium in Hollywood, Fla.

Feature | Breast Imaging | April 24, 2019 | By Greg Freiherr
Wires have traditionally been placed prior to lumpectomy to mark cancerous tissues in the breast.
News | Biopsy Systems | March 29, 2019
Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy...
FDA Clears Ion Endoluminal Lung Biopsy System
Technology | Interventional Radiology | February 20, 2019
The U.S. Food and Drug Administration (FDA) cleared the Ion endoluminal system from Intuitive Surgical Inc. to enable...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Philips’ Compressed SENSE technology helps shorten MRI exams by eliminating redundant radiofrequency signals from the acquisition phase. The software reconstructs any missing  information to maintain high image quality. (Images courtesy of Philips/University Hospital Cologne)

Philips’ Compressed SENSE technology helps shorten MRI exams by eliminating redundant radiofrequency signals from the acquisition phase. The software reconstructs any missing information to maintain high image quality. (Images courtesy of Philips/University Hospital Cologne)

Feature | Breast Imaging | November 05, 2018 | By Jeff Zagoudis
The incidence of breast cancer is rising globally, with an estimated 1 in 8 women diagnosed in their lifetime and 40,...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to
Leica Biosystems Launches MammoPort Specimen Containment and Transport System
Technology | Breast Biopsy Systems | October 03, 2018
Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...